| |
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now.
|
|
Today’s Big NewsJan 2, 2024 |
| By Kevin Dunleavy Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. In 2023, the FDA gave a thumbs up to more than 60 new treatments, a significant increase from 2022, when only 37 drugs passed muster. |
|
|
|
By Gabrielle Masson Biopharma layoffs rose 57% last year compared to 2022, with 187 industry workforce reductions in 2023 compared to 119, according to an analysis of Fierce Biotech data. |
By Fraiser Kansteiner While public and political scrutiny around drug pricing has reached a fever pitch in the wake of 2022’s Inflation Reduction Act (IRA), that hasn’t stopped pharma majors from ringing in 2024 with their favorite New Year tradition: a hefty round of price hikes. |
By Conor Hale Roche aims to gain a selection of products from the flagging LumiraDx, including a shoebox-sized analyzer and a menu of specialized tests. |
|
Wednesday, January 24, 2024 | 2pm ET / 11am PT Join industry experts to hear how digital collection of patient-reported outcomes (PROs) can lay the foundation for advancing health equity, which methods can ensure that PROs are relevant for diverse populations, and what challenges and opportunities still lie ahead. Register now.
|
|
By Annalee Armstrong What do you get when you halve the number of seizures across a group of difficult epilepsy disorders in an early-stage trial? For Longboard Pharmaceuticals, you get a tripling of your share price. |
By Fraiser Kansteiner At the end of November, more than 1.5 million courses of Pfizer’s Paxlovid had expired unused in European countries, analysts at Airfinity said in a new report. The total tally of expired doses in Europe is expected to hit 3.1 million by the end of next month, representing a value of $2.2 billion. |
By Zoey Becker According to a recent securities filing, AbbVie only entered the ImmunoGen bidding war after other buyout interest led the ADC specialist to widen its pool of potential purchasers. When it came down to the final three players, AbbVie's offer blew the others out of the water. |
By Andrea Park The Mayo Clinic is doubling down on artificial intelligence to kick off 2024. |
By Annalee Armstrong You think Santa can stop the biotech deal making train? Think again. A handful of companies couldn’t wait for the New Year—or next week’s JP Morgan Healthcare conference—to announce their latest wheeling and dealing. We recap the Christmas deal spree. |
By Gabrielle Masson Anavex Life Sciences’ lead asset has failed to significantly improve disease characteristics in a pediatric Rett syndrome trial, with the company pointing the blame toward a high placebo effect. |
By Andrea Park In the wake of warnings from the FDA about safety issues associated with certain ultrasound-equipped endoscopes, EndoSound has secured an agency clearance for a device designed to avoid those issues. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
|
This resource describes some key factors worth considering as you think through how to construct an effective and robust screening cascade. We will focus initially on the hit-to-lead phase, as this encompasses the types of assays required and highlights some general considerations. Download now.
|
|
| WhitepaperDiscover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperqPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range Sponsored by: Diversigen |
| WhitepaperStreamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements. Sponsored by: Aldevron |
| Whitepaper High performance computing (HPC) combined with artificial intelligence (AI) and machine learning (ML) can speed up research and development processes and dramatically reduce reliance on expensive clinical trials. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
| Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| |
|
